Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Pre-order your Brochure
Reserve your place

Your Speaker Faculty

We are currently putting together the agenda and speaker list for 2018. If you would like to be part of the research or join the speaking faculty, please put forward your suggestions to gquartin@eyeforpharma.com


Melissa McGregor

Melissa McGregor

Managing Director, Pfizer

Read more

More information coming soon...

David Kwasha

David Kwasha

VP & Managing Director, JAPAC Region, Alexion Pharmaceuticals

Read more

David’s career has been one of broad experience in hospital and primary health care, commencing with Intensive Care and Critical Care nursing in his youth until 26 years of age and the last 28 years marked by a unique and very successful management career in the pharmaceutical industry with medical, marketing, commercial and senior leadership depth in the pharmaceuticals and biotechnology industries. His background qualifications are in Nursing Science (he was a practicing Clinical Nurse Specialist in ICU for 6 years) with post graduate qualifications in marketing and business management developed during his pharmaceutical career..

Prior to joining Alexion in July 2008, to lead the introduction of unique biological products for ultra-rare and life threatening diseases in Asia Pacific, David was Vice President, Asia Pacific and Australian Managing Director of the Swiss biopharmaceutical company, Actelion from 2001 - 2008. From 1990 – 2001 David worked in a variety of medical, marketing, and business unit management roles in Australia and Globally for Roche in their Swiss HQ as a Global Business and Lifecycle Leader from 1997 - 2001.

For the past 17 years, David’s professional passion has been driven by branching out into the unique area of life threatening rare disease and he has focused working with companies with clear breakthrough drugs for such seriously life threatening indications. This passion is driven by his deep belief that no person inflicted with a serious rare disease should be penalized by the fact the disease is not a common and hence not so attractive to the large investments required to achieve development of therapy and solutions to save lives. He was able to further pursue his deep interest in making a difference for sufferers of life threatening ultra - rare disease by joining Alexion Inc when Soliris was recognized worldwide in 2008 with a Prix Gallien Award (US and France) as the world’s greatest breakthrough in biological medicine that year. Alexion has now grown to the point that it is clearly a world leader in both developing and launching new breakthrough therapies for ultra-rare disease..

David has also worked on Australian government working groups and committees such as the Pharmaceutical Education Council (2005 – 2008) and Chaired the Medicines Australia Biotechnology Working Group (MABIG) in 2006. This work enabled David to contribute to the development of reimbursement policies for biotechnology and rare disease sector within Australia.

In addition to David’s work in the pharmaceutical industry, he has also diversified in the past into leadership training and coaching with the well-recognized leadership thought leader, author and media commentator, Avril Henry, including contributing to her best-selling book in 2008 – “Tomorrows Leaders Today – Breaking Down Generational Barriers at Work”.

Michala Fisher Hansen

Michala Fischer-Hansen

VP & GM/MD- Australia and New Zealand, Novo Nordisk

Read more

Michala Fischer-Hansen is the Managing Director of the Oceania region (Australia & New Zealand), Novo Nordisk Pharmaceuticals Pty Ltd, a role she has held since April 2016.

Michala holds an extensive experience within the pharmaceutical industry, having worked in Novo Nordisk for 17 years. Michala has held positions in Novo Nordisk Headquarter in the area of global strategy and execution, specifically, within pricing, pharmacoeconomics, strategic marketing and management and communication. Michala has also worked for the Novo Nordisk US organisation, where she worked in the commercial part of the business within Marketing Effectiveness.

In 2014 Michala returned to Novo Nordisk Denmark as Senior Global Marketing Director and was in June 2015 promoted to Corporate Vice President in Global Marketing. In this role, Michala was responsible for the commercialisation, global rollout and life cycle management of a new line of diabetes products.

Michala holds a Masters degree in International Business from Copenhagen Business School and is a Danish citizen.

Kirsten O’Doherty

Kirsten O’Doherty

General Manager ANZ, Abbvie

Read more

Kirsten O’Doherty is the ANZ General Manager of biopharmaceutical company, AbbVie where she leads a team of 300+ staff across Australia and New Zealand. She is a member of the AbbVie regional leadership team in Asia, including Japan.

AbbVie is focused on discovering, developing, and delivering medicines in therapeutic areas where the company has proven expertise and where the most impact can be made. These areas include immunology, oncology, virology and neuroscience. For five years in a row, AbbVie has been recognised on the Australian Financial Review’s Most Innovative Companies list and has been named one of Australia’s ‘Best Places to Work’ for several consecutive years.

Originally qualified and working as a hospital pharmacist, Kirsten’s career has subsequently spanned more than 20 years in the Australian pharmaceutical industry, moving from initial clinical research and medical roles to commercial roles, and finally into senior leadership roles. Throughout her career, Kirsten has remained committed to continuing professional development. She is a Graduate of the Australian Institute of Company Directors, and has undertaken residential senior leadership programs at the London Business School, and at IMD in Switzerland.

Kirsten has a breadth and depth of experience including leadership of financial performance, marketing and sales excellence, strategic planning, change management and creating high levels of employee engagement.

Kirsten is on the Board of Medicines Australia, the industry association for the pharmaceutical industry in Australia and is the Chair of the Nominations committee.

Shaun Holmgreen

Shaun Holmgreen

Head, Operational Excellence, UCB

Read more

More information coming soon...

Saul Resnick

Saul Resnick

CEO Australia, New Zealand and Life Science Healthcare APAC, DHL Supply Chain

Read more

More information coming soon...

Adrian Bootes

Adrian Bootes

Assistant Secretary, Prescription, Therapeutic Goods Association

Read more

Adrian is Assistant Secretary, TGA in charge of the Prescription Medicines Authorisation Branch. Adrian has had a 25 year career as a health care professional, professional board member, CEO of ARCS and serving in clinical research and regulatory affairs management for major pharma. In addition to running a busy branch and supporting delivery and improvements of current TGA medicine review processes, Adrian has been recently involved in the delivery of the prescription medicines component of the government’s response to the Expert Review into Medicines and Medicines Devices.

Simon McErlane

Simon McErlane

Senior Medical Leader, Amicus Therapeutics

Read more

More information coming soon...

Mark Edwards

Mark Edwards

Digital Strategy Lead, Pfizer

Read more

More information coming soon...

Lynn Saroti

Lynn Saroti

Director Medical Affairs, Alexion

Read more

More information coming soon...

Andrew Weeks

Andrew Weeks

Medical Director, GSK Australia

Read more

Andrew Weekes is a UK-trained doctor with almost 20 years of experience in pharmaceutical medicine. He joined the industry in 1999 following junior hospital jobs, a short stint in general practice, and a period as a medical advisor and in-flight medic with a UK-based air ambulance company. His first pharma role was as International Scientific Project Manager based in the Paris headquarters of a mid-sized company, where he remained for 4 years before seeking in-country experience which brought him to Melbourne. He held positions of increasing seniority in the Australian office, ending as Head of Medical Department, before moving back to Europe to take up the position of UK Medical Director. The UK role expanded his experience into market access with leadership of the UK regulatory affairs and health economics functions. He then returned to Australia for a Sydney-based Country Medical Director role at Abbott Australasia, with managing the medical and clinical research functions for Abbott and AbbVie through their 2012 global corporate separation and the first 2 years of AbbVie Australasia. Andrew returned to Melbourne in November 2014 as Country Medical Director at GSK, leading the clinical research, drug safety, medical information, medical quality and medical affairs functions. In addition to his medical degree Andrew has a Graduate Diploma in Drug Evaluation and Pharmaceutical Science, and a qualification in Aviation Medicine. He enjoys a range of outdoor pursuits and spending time with his young family.

Tracey Scrivens

Tracey Scrivens

Digital Strategy Manager, Roche

Read more

More information coming soon...

Richard Clement

Richard Clement

Group Digital Marketing Manager, Aspen

Read more

Richard has been working in the Pharma and Life Sciences space since graduating as a Molecular Biologist in the late eighties. He has worked in sales and sales management, marketing and training until joining Aspen in 2005 to take on the challenge of providing digital tools to support both sales force and customers. Richard is now Group Digital Manager for Aspen Pharma and with his small global team oversees web, mobile and social media aspects of the larger Aspen business.

Carol Ireland

Carol Ireland

CEO, Epilepsy Action Australia

Read more

More information coming soon...

Lisa Murphy

Lisa Murphy

Interim CEO, Kidney Australia

Read more

Lisa Murphy has been with Kidney Health Australia since 2016, initially as the National Kidney Cancer Program General Manager, moving into a Medical Advisor role and then into her current usual role as General Manager for KHA Research. Lisa is keen to maintain the momentum at Kidney Health Australia in supporting Australians affected by kidney disease through our focus on Community, Advocacy and Research.

Lisa qualified as a medical doctor in the UK with a board scientific and medical training including; a 1st class honours degree in psychology and physiology, a degree in Medicine from Imperial College London, post graduate certification in medicine (MRCP) and specialist training in anaesthetics and intensive care.

Lisa moved to Melbourne with her family in 2010. In looking after her 2 sons who have type 1 diabetes, Lisa embarked on a career change, initially in medical writing and education and then into the For Purpose sector. When not at work Lisa loves spending time with her boys and cycling.

Deidre MacKechnie

Deidre MacKechnie

CEO, MS Australia

Read more

Deidre is the CEO of MS Australia, the national peak advocacy body for people living with MS in Australia. Deidre commenced with MS Australia in early 2013 in the role of Executive Officer and Company Secretary before her appointment as CEO in 2015. Deidre has had an extensive career in Health, initially training as a nurse which led to clinical education, followed by a move to Human Resources and subsequent roles in senior management. Deidre has post graduate qualifications in Education, Human Resource Management and Governance.

Richard Vines

Richard Vines

CEO, Rare Cancer

Read more

Richard attended University of Melbourne where he studied Maths and Statistics. He then trained as an Actuary but was inspired to join the fledging IT industry before qualifying. After several years working in software development, Richard formed his own software company which he then sold in 1990 before embarking on a second software venture in Europe. In 1996, Richard returned to Australia where he was retained by an American company to establish a sales channel in Australia. In 2001, Richard left IT to work in a number of not-for-profits associated with retail, politics and health. In 2012 Richard and his wife Kate established Rare Cancers Australia, a patient advocacy group, whose mission is to improve the lives and outcomes for rare cancer patients. Richard is now a highly sort after spokesperson for cancer patient advocacy issues.

Giselle Quartin

Giselle Quartin

Head of Asia-Pac
eyeforpharma

Phone: +44 (0) 207 375 7176

Email: gquartin@eyeforpharma.com

Pre-order the detailed event brochure

Complete speaker line-up • Program for all tracks & sessions • Audience breakdown